Send us Fan Mail

The landscape of medication to treat ER+, HER2 negative or low is changing rapidly as patients experience progression on CDK4/6 inhibitors and look for next steps.  Now that biomarker testing is more readily available (both tissue and liquid), there are more options particularly in the PI3 kinase pathway.  In this episode we will discuss biomarker testing, the PI3 kinase pathway, and an exciting new patient initiative, the PIK3CA Pathbreakers.

We’re so happy you joined us! If this conversation resonated with you please share it with someone who might need it. Don't forget to like and subscribe here to follow us on your favorite podcast platform so you never miss an episode. You can find more episodes, resources and ways to get involved on our website Our MBC Life. Have a topic you’d like us to cover? Email us at [email protected]. And don’t forget to follow us on our socials @ourmbclife. 

Remember you are not alone.